Folate Metabolism in T-Cell Activation: Impact on CAR-T Cell Therapy Efficacy

Cancer immunotherapy has transformed the treatment landscape for hematological malignancies and is rapidly expanding into solid tumors. Among these innovations, CAR-T cell therapy has emerged as one of the most powerful personalized treatment strategies. Yet despite remarkable clinical successes, many patients still experience relapse, limited persistence of engineered T cells, or poor responses in immunosuppressive tumor environments. Increasingly, researchers are discovering that cellular metabolism may determine whether CAR-T therapy succeeds or fails.

One metabolic pathway attracting major attention is folate-mediated one-carbon metabolism. Far beyond its traditional nutritional role, folate metabolism directly shapes T-cell activation, proliferation, DNA synthesis, epigenetic regulation, and immune persistence. Understanding how folate metabolism supports T-cell fitness is now becoming essential for improving CAR-T manufacturing, enhancing anti-tumor activity, and overcoming the hostile tumor microenvironment.

The Link Between One-Carbon Metabolism and CAR-T Cell Fitness

CAR-T therapy depends on the generation of highly functional T cells that can survive, proliferate, and maintain cytotoxicity after infusion into patients. Metabolic programming strongly influences whether these engineered cells remain effective over time.

Different T-cell subsets rely on distinct metabolic strategies. Effector T cells primarily depend on glycolysis to support rapid inflammatory responses, while long-lived memory T-cell populations such as TSCM cells preferentially utilize oxidative phosphorylation (OXPHOS) and fatty acid oxidation (FAO). Because durable CAR-T responses are closely associated with memory-like phenotypes, metabolic optimization has become a major focus in next-generation CAR-T engineering.

Folate metabolism intersects with these pathways at multiple levels. Efficient nucleotide synthesis supports sustained proliferation during CAR-T manufacturing, while proper methylation balance helps regulate differentiation and cell fate decisions. Inadequate folate metabolism may push CAR-T cells toward terminal differentiation and exhaustion instead of long-term persistence.

Researchers are now exploring how metabolic conditioning during ex vivo expansion can improve CAR-T quality. Adjusting cytokine combinations such as IL-15 and IL-21, optimizing nutrient composition, and fine-tuning mitochondrial metabolism have all shown promise in generating more resilient CAR-T products.

Importantly, the choice of CAR co-stimulatory domain also affects metabolic behavior. CAR constructs containing CD28 signaling often promote glycolytic metabolism associated with rapid effector activity, whereas 4-1BB-based CARs favor oxidative phosphorylation and fatty acid oxidation, supporting greater persistence in vivo. These metabolic differences may influence how efficiently CAR-T cells utilize folate-dependent biosynthetic pathways.

How the Tumor Microenvironment Disrupts CAR-T Metabolism

Even highly optimized CAR-T cells face major challenges after entering solid tumors. The tumor microenvironment (TME) creates a metabolically hostile ecosystem characterized by nutrient deprivation, hypoxia, acidic stress, and immunosuppressive signaling.

Tumor cells aggressively consume glucose, amino acids, and other nutrients needed by activated T cells. At the same time, cancer-associated metabolic reprogramming generates high levels of lactate, reactive oxygen species (ROS), and adenosine, all of which suppress immune function.

Immunosuppressive cell populations further intensify this problem. Myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and regulatory T cells (Tregs) collectively inhibit CAR-T expansion, cytokine production, and cytotoxic activity.

Because folate metabolism is tightly connected to nucleotide synthesis and mitochondrial fitness, disruption of nutrient availability within the TME may directly impair one-carbon metabolic flux in CAR-T cells. Over time, this metabolic pressure can contribute to exhaustion and functional collapse.

Researchers are therefore investigating whether metabolic support strategies could help CAR-T cells remain functional under nutrient-limited conditions.

Metabolic Engineering Strategies to Enhance CAR-T Performance

As CAR-T therapies expand into solid tumors, metabolic engineering is becoming a central strategy for improving therapeutic durability.

Several promising approaches are under active investigation:

Enhancing Mitochondrial Function

Promoting oxidative phosphorylation and mitochondrial biogenesis may improve CAR-T persistence and resistance to exhaustion. Agents that activate mitochondrial regulators such as PGC1α are being explored to reinforce long-term cellular fitness.

Reducing Excessive Glycolysis

Although glycolysis supports rapid effector responses, excessive glycolytic dependence can accelerate terminal differentiation. Controlled inhibition using agents such as 2-deoxyglucose (2-DG) may help preserve memory-like CAR-T phenotypes.

Optimizing Ex Vivo Expansion Conditions

Manufacturing conditions strongly influence metabolic programming. Adjusting nutrient composition, oxygen levels, cytokine exposure, and folate-related metabolites during cell expansion could generate more metabolically resilient CAR-T products.

Engineering Superior CAR Designs

The selection of co-stimulatory domains significantly shapes metabolic behavior. 4-1BB-containing CARs often demonstrate enhanced oxidative metabolism and improved persistence compared with CD28-driven constructs.

Targeting One-Carbon Metabolism Directly

Future strategies may involve fine-tuning folate-dependent pathways to support nucleotide synthesis, epigenetic stability, and resistance to exhaustion without simultaneously fueling tumor growth.

The Future of Folate-Guided CAR-T Therapy

The next generation of CAR-T therapies will likely rely not only on genetic engineering but also on sophisticated metabolic optimization. Folate metabolism sits at the center of this emerging field because it directly controls the biosynthetic and epigenetic programs that determine T-cell activation, persistence, and anti-tumor activity.

By improving one-carbon metabolic fitness, researchers may be able to generate CAR-T cells that survive longer, resist exhaustion, and function more effectively inside hostile tumor microenvironments. At the same time, FOLR1-targeted strategies continue to show strong promise for expanding CAR-T therapy into difficult-to-treat solid tumors.

As immunometabolism research advances, folate-related pathways may become key therapeutic levers for enhancing precision cellular immunotherapy and improving outcomes for patients with refractory cancers.

Folate & Vitamin B12 Antibodies

Folate & Vitamin B12 Antigen

Folate & Vitamin B12 ELISA